PATENT CLAIM ANALYSIS

Application Number: 16050798
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["514", "374000"]

Abstract:
The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A 2  receptor antagonist.

Claim (Index 10):
The method of  claim 3 , wherein the thromboxane A 2  receptor antagonist is administered prophylactically to prevent cardiomyopathy in the patient.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 95.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15592727', '14715143', '15608507', '16004666', '14391484']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.79949899200464
- 35 USC 102 Novelty (BERT): 0.6800554790299633
- Combined Prediction Score: 0.7875546407071723
- Mean Citation Score: 461.43218199999984
- Max Citation Score: 707.84644
- Similarity Product: 639.3569660209034

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test